SCHEMBL366501

SCHEMBL366501

CS(=O)(=O)NC(=O)c1ccc(OCc2ccc(C#N)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.62
SMPD1 P17405 1/20 0.57
SCN9A Q15858 3/20 0.53
ALDH1A1 P00352 3/20 0.51
MAPT P10636 3/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
ADAM17 P78536 1/20 0.50
ADAMTS4 O75173 1/20 0.50
MMP13 P45452 1/20 0.50
SCN3A Q9NY46 1/20 0.49
BCL2L1 Q07817 1/20 0.49
MCL1 Q07820 1/20 0.49
MAOB P27338 2/20 0.49
CYP19A1 P11511 1/20 0.48
SPHK2 Q9NRA0 1/20 0.47
SPHK1 Q9NYA1 1/20 0.47
GUSB P08236 1/20 0.47
AR P10275 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16239638 1.00 RAB9A (0.62) RAB9ASMPD1SCN9AALDH1A1MAPT
SCHEMBL365645 0.85 ALDH1A1 (0.70) RAB9ASMPD1SCN9AALDH1A1MAPT
SCHEMBL364340 0.85 RXRA (0.62) RAB9ASCN9AALDH1A1MAPTMAPK1
SCHEMBL16239768 0.85 ALDH1A1 (0.70) RAB9ASMPD1SCN9AALDH1A1MAPT
SCHEMBL5484295 0.85 SMPD1 (0.76) RAB9ASMPD1ALDH1A1MAPTMAPK1
SCHEMBL22247186 0.85 SMPD1 (0.50) RAB9ASMPD1SCN9AALDH1A1MAPT
SCHEMBL20943254 0.85 MAOA (0.55) RAB9ASCN9AALDH1A1SCN3AMAOB
SCHEMBL365210 0.84 MAOA (0.63) RAB9ASCN9AALDH1A1MAPTMAPK1
SCHEMBL366812 0.84 MAOB (0.63) SCN9AALDH1A1MAPTMAPK1HTT
SCHEMBL366081 0.84 MAOA (0.63) RAB9ASCN9AALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A RAB9A 987/4885SMPD1 542/4885SCN9A 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.